GPC1 and familial pancreatic carcinoma: As a potential therapeutic target, an anti-GPC1 monoclonal antibody (GPC1 mAb) drug conjugate has been developed and has shown excellent preclinical in vivo antitumor effects in pancreatic cancer models (7,13).